International Journal of Clinical Oncology and Cancer Research
Volume 2, Issue 2, April 2017, Pages: 29-30
Received: Sep. 14, 2016;
Accepted: Mar. 3, 2017;
Published: Mar. 15, 2017
Views 2114 Downloads 337
Md Kamrul Hasan, Moores Cancer Center, University of California San Diego, CA, USA
Breast cancer is one of the most deadly diseases all over the world. Recent findings suggest that HER2+ and HER2- Circulating Tumour Cells (CTCs) of metastatic breast cancer interconvert spontaneously and combined treatment with paclitaxel and Notch inhibitors achieves sustained suppression of tumorigenesis implicating novel therapeutic strategy to treat this devastating disease.
Md Kamrul Hasan,
HER2 Dynamics: Advances in Breast Cancer Treatment, International Journal of Clinical Oncology and Cancer Research.
Vol. 2, No. 2,
2017, pp. 29-30.
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/
) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Guiu S, Michiels S, Andre F, Cortes J, Denkert C, Di Leo A, et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2012 Dec; 23 (12): 2997-3006.
Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2010 May; 23 Suppl 2: S60-64.
Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer biology & therapy 2010 Nov 15; 10 (10): 955-960.
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. American journal of cancer research 2015; 5 (10): 2929-2943.
Santa-Maria CA, Gradishar WJ. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned. JAMA oncology 2015 Jul; 1 (4): 528-534; quiz 549.
Marquette C, Nabell L. Chemotherapy-resistant metastatic breast cancer. Current treatment options in oncology 2012 Jun; 13 (2): 263-275.
Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast cancer research: BCR 2010; 12 Suppl 2: S2.
Wong ST, Goodin S. Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy 2009 Aug; 29 (8): 954-965.
Joensuu H. Escalating and de-escalating treatment in HER2-positive early breast cancer. Cancer Treat Rev 2016 Nov 10; 52: 1-11.
Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, et al. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. J Cell Physiol 2016 Nov 11.
Altundag K. First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer. Breast cancer research and treatment 2016 Nov 17.
Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer cell 2014 Mar 17; 25 (3): 282-303.
Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast cancer research and treatment 2011 Oct; 129 (3): 659-674.
Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature 2016 Aug 24; 537 (7618): 102-106.